Salvinorin molecule:

Image from PubChem

Salvinorin Clinical Trials

A Double Blind Placebo Controlled Ascending Dose Pharmacodynamic and Tolerability Study of 100 to 4000 µg of Sublingual Salvinorin A

To see complete record on, please visit this link

Id: NCT01149824

Organisation Name: California Pacific Medical Center Research Institute

Overal Status: Completed

Start Date: June 2009

Last Update: May 31, 2013

Lead Sponsor: California Pacific Medical Center Research Institute

Brief Summary: In this study, our aim is to determine an active but tolerable sublingual dose (range 100 to 4000 µg) of Salvinorin A (SA) in experienced subjects. This study is an ascending-dose, placebo-controlled, single-site design in 8 Salvia-experienced subjects. Subjects will receive SA doses from 0-4000 µg. Doses will be separated by at least one day. The first two doses (0 and 100µg) will be double-blinded while the last four (250, 500, 1000, 2000 and 4000µg) will be single-blind.

  • Pharmaceutical Preparations

Total execution time in seconds: 0.31913995742798